A novel nasal treatment developed to boost the human immune system to fight common colds and flu has proved successful in reducing COVID-19 viral growth in a recent animal study.

This is a significant development as the world races to find a solution to halt COVID-19 transmission and infection.

The INNA-051 compound works by stimulating the innate immune system, the first line of defence against the invasion of pathogens into the body. By boosting the immune response in this way with INNA-051 prior to infection, the ability of the COVID-19 virus to infect the animals and replicate was dramatically reduced the PHE study showed. The study provides evidence that INNA-051 can be used as a stand-alone method of antiviral preventative therapy, complementary to vaccine programs.

A biotech company in Australia says that its nasal spray reduces the growth of corona virus. This result was found in a study done on animals. However, the company started work on this nasal spray to improve the immune system of people suffering from common cold and flu. 

According to a Reuters report, the company called 'Ana Respiratory' says that the product named INNA-051 was studied above the ferret organism. During this period, it was found that nasal spray reduces the corona virus by up to 96 percent. 

If the nasal spray INNA-051 is successful in the next round of trials, it can be used along with the vaccine. The initial study was led by the UK government agency Public Health England.